Infliximab for Injection
Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
The first infliximab biosimilar marketed in China
Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.
Indications:
Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Recommended reading
Related products
-
Gel & Clot Activator Tube
Contact UsGel and clot activator tube is used for blood serum biochemistry, immunology and drug testing, etc.
-
The Latest 5-in-1 Car Jump Starter and Tire Inflator
Contact UsThis innovative device combines four essential functions in one compact unit, ensuring you’re well-equipped for any roadside emergency or outdoor adventure.
-
Bulb Flat
Contact UsBulb Flat Steel is mainly used in shipbuilding, marine engineering, steel structure engineering, and bridge engineering.Most ships choose ball-flat steel for structural design.
-
Metal casings
Contact UsYancheng Zhongming New Materials Co., Ltd. is located in Yancheng City, Jiangsu Province.
Reviews
There are no reviews yet.